If you’re not too early, you’re too late | Shelby Newsad, Partner at Compound VC

12 snips

Apr 10, 2025

Shelby Newsad, a Partner at Compound VC, is passionate about advancing technologies in bio and health. She shares her journey from a small-town background to a prominent role in biotech investing. The discussion dives into the crucial transition from academia to real-world applications, highlighting what makes a strong investment thesis. Shelby also explores the fascinating world of biohacking and emerging health technologies, emphasizing the balance between innovation and accessibility. Her insights promote an optimistic view of future advancements in science and healthcare.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

ANECDOTE

Commercialization Bottleneck

Shelby Newsad realized commercialization's importance when unpublished data on acetaminophen's cancer-killing potential went unnoticed.
The bottleneck wasn't research but getting people to care and navigating regulatory processes.

INSIGHT

Ecosystem Awareness

Academia incentivizes focusing solely on research, neglecting the broader ecosystem.
Scientists should gain broader industry context, similar to finance professionals understanding diverse financial sectors.

ADVICE

High-Context Investing

Be a high-context thought partner by deeply understanding your companies' fields.
Help founders with hiring, milestones, and connecting technical unlocks to commercial opportunities.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

In this episode of the Nucleate Podcast, Anastasia Janas sits down with Shelby Newsad, Partner at Compound VC, shares her journey from a small town in Appalachia to investing in some of the most transformative technologies shaping biotech and beyond. Starting as a first-generation college student with a pre-med background, she realized that commercialization is key to translating scientific research into real-world impact.

Shelby discusses her work at Compound, a thesis-driven, research-centric venture firm investing across AI, robotics, crypto, and biotech. She explains how Compound builds deep expertise in emerging fields — developing theses, connecting with researchers, and creating ecosystems around transformational areas — to become the highest-context investors for early-stage companies. When critical gaps in the market appear, Compound even incubates companies themselves, such as in plant engineering for high-value, lower-regulation products.

The conversation dives into emerging trends like autonomous science, science-driven consumer products, biohacking, and proactive healthcare. Shelby highlights the importance of individual health data ownership, the potential for brain modulation technologies, and why bold, contrarian founders are key to the future of biotech. She shares her optimism for the future, from conservation tech to cancer prevention, and invites listeners to think bigger, move earlier, and reach out with innovative ideas — and to get involved with Compound’s upcoming Research Days in San Francisco.

Time Stamps

00:04 - 00:27: Introduction about research days in San Francisco

00:27 - 01:11: Intro about Shelby

01:11 - 03:06: Shelby’s background and fascination for science

03:06 - 10:54: Discussion about translation from academia to real-world products

0:10:54 - 21:12: Compound's investment approach & what makes a good thesis

21:12 - 24:15: Compound’s incubation model

24:15 - 30:06: What Shelby looks for when meeting founders

30:06 -37:06: Conversation about biohacking and medical perspectives

37:06 - 40:09: Discussion about potential future technologies

40:09 - 41:32: Contact information and upcoming research days

41:32 - 45:32: Closing thoughts about scientific optimism

FInd more about the Podcast at the Signal Website